Abstract:Liquid biopsy methodologies, for the purpose of plasma genotyping of cell-free DNA (cfDNA) of solid tumors, are a new class of novel molecular assays. Such assays are rapidly entering the clinical sphere of research-based monitoring in translational oncology, especially for thoracic malignancies. Potential applications for these blood-based cfDNA assays include: (i) initial diagnosis, (ii) response to therapy and follow-up, (iii) tumor evolution, and (iv) minimal residual disease evaluation. Precision medicine will benefit from cutting-edge molecular diagnostics, especially regarding treatment decisions in the adjuvant setting, where avoiding over-treatment and unnecessary toxicity are paramount. The use of innovative genetic analysis techniques on individual patient tumor samples is being pursued in several advanced clinical trials. Rather than using a categorical treatment plan, the next critical step of therapeutic decision making is providing the "right" cancer therapy for an individual patient, including correct dose and timeframe based on the molecular analysis of the tumor in question. Per the 21st Century Cures Act, innovative clinical trials are integral for biomarker and drug development. This will include advanced clinical trials utilizing: (i) innovative assays, (ii) molecular profiling with cutting-edge bioinformatics, and (iii) clinically relevant animal or tissue models. In this paper, a mini-review addresses state-of-the-art liquid biopsy approaches. Additionally, an on-going advanced clinical trial for lung cancer with novelty through synergizing liquid biopsies, co-clinical trials, and advanced bioinformatics is also presented. Impact statement Liquid biopsy technology is providing a new source for cancer biomarkers, and adds new dimensions in advanced clinical trials. Utilizing a non-invasive routine blood draw, the liquid biopsy provides abilities to address perplexing issues of tumor tissue heterogeneity by identifying mutations in both primary and metastatic lesions. Regarding the assessment of response to cancer therapy, the liquid biopsy is not ready to replace medical imaging, but adds critical new information; for instance, through a temporal assessment of quantitative circulating tumor DNA (ctDNA) assay results, and importantly, the ability to monitor for signs of resistance, via emerging clones. Adjuvant therapy may soon be considered based on a quantitative cfDNA assay. As sensitivity and specificity of the technology continue to progress, cancer screening and prevention will improve and save countless lives by finding the cancer early, so that a routine surgery may be all that is required for a definitive cure.

Liquid Biopsy in Neuropsychiatric Disorders: A Step Closer to Precision Medicine

Liquid Biopsy in Neurological Diseases

Cell-free DNA-based liquid biopsies in neurology

Liquid biopsy in CNS tumors: Current status & future perspectives

The potential of circulating cell-free RNA in CNS tumor diagnosis and monitoring: A liquid biopsy approach

Unveiling brain disorders using liquid biopsy and Raman spectroscopy

The Utility of Liquid Biopsy in Central Nervous System Malignancies

The functional and clinical roles of liquid biopsy in patient-derived models

Precision medicine for psychotic disorders: objective assessment, risk prediction, and pharmacogenomics

Current challenges and best practices for cell-free long RNA biomarker discovery

Liquid biopsy: creating opportunities in brain space

Emergence of Extracellular Vesicles as "Liquid Biopsy" for Neurological Disorders: Boom or Bust

Liquid biopsy and its role in an advanced clinical trial for lung cancer

Liquid Biopsies: DNA Methylation Analyses in Circulating Cell-Free DNA

Liquid biopsy: current technology and clinical applications

Biomarker-Drug and Liquid Biopsy Co-development for Disease Staging and Targeted Therapy: Cornerstones for Alzheimer’s Precision Medicine and Pharmacology

Liquid Biopsy: A Distinctive Approach to the Diagnosis and Prognosis of Cancer

Liquid Biopsy: A New, Non-Invasive Early Diagnostic and Prognostic Tool in Oncology

Liquid biopsy: a step forward towards precision medicine in urologic malignancies

GEN-7 Liquid biopsy in brain tumor patients -The present and future-

Applications of cerebrospinal fluid circulating tumor cells and circulating tumor-derived DNA in diagnosis, prognosis, and personalized treatment of CNS metastases